Navigation Links
Scientists discover new way to target cancer
Date:12/12/2011

Scientists have discovered a new way to target cancer through manipulating a master switch responsible for cancer cell growth.

The findings, published today [12 Dec] in the journal Cancer Cell, reveal how cancer cells grow faster by producing their own blood vessels.

Cancer cells gain the nutrients they need by producing proteins that make blood vessels grow, helping deliver oxygen and sugars to the tumour. These proteins are vascular growth factors like VEGF the target for the anti-cancer drug Avastin. Making these proteins requires the slotting together of different parts of genes, a process called splicing.

Scientists at UWE Bristol and the University of Bristol discovered that mutations in one specific cancer gene can control how splicing is balanced, allowing a master switch in the cell to be turned on. This master switch of splicing makes cancer cells grow faster, and blood vessels to grow more quickly, as they alter how VEGFs are put together.

In experimental models, the researchers found that by using new drugs that block this master switch they prevented blood vessel growth and stopped the growth of cancers.

Dr Michael Ladomery spearheading the work from UWE Bristol, said: "The research clearly demonstrates that it may be possible to block tumour growth by targeting and manipulating alternative splicing in patients, adding to the increasingly wide armoury of potential anti-cancer therapies."

Professor David Bates who led the team from the University of Bristol's School of Physiology and Pharmacology, said: "This enables us to develop new classes of drugs that target blood vessel growth, in cancer and other diseases like blindness and kidney disease."

The work, which started on kidney cancer, also involved groups at Southmead Hospital, where patients with kidney disease helped by allowing tissues that had been removed during surgery to be used in the research.

Professo
'/>"/>

Contact: Caroline Clancy
caroline.clancy@bristol.ac.uk
44-011-792-88086
University of Bristol
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Survey reveals scientists have trouble accessing human embryonic stem cell lines
2. Scientists capture single cancer molecules at work
3. Scientists identify strategies to conquer lifestyle and genetic factors related to chronic diseases
4. Scientists discover likely cause of most common involuntary movement disorder
5. Scientists ID Gene That Predicts Chances of Cold Sores
6. Scientists discover anti-inflammatory polyphenols in apple peels
7. Scientists identify key area that could sever communication between brain and heart in disease
8. Scientists identify defect in brain cell channel that may cause autism-like syndrome
9. Scientists Reveal Monarch Butterfly Genome
10. Scripps Research scientists identify new class of antimalarial compounds
11. NIH-funded scientists identify potential malaria drug candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Hands On Mobile Spa, has announced they now have a ... been transformed into a utopia for the Long Island community ... The Virtual Tour showcases the beauty of the Spa On ... more. , The Virtual Tour shows viewers each of the ... overhauled Winnebago. Marla Kaplan-Pelle, Director states " It's hard to ...
(Date:12/19/2014)... December 19, 2014 After a 13-year ... is again returning to the stage to entertain his ... for concert performances, and the successful tour has been ... announced. , Visit Ticketability.com for a ... Detroit shows at fair prices. , Music fans have ...
(Date:12/19/2014)... Dec. 18, 2014 (HealthDay News) -- A new study ... moderate to severe hot flashes and night sweats -- ... Hot flashes are common during menopause, affecting about ... also affect women after menopause, since they then face ... "Our findings suggest women who exhibit moderate or severe ...
(Date:12/19/2014)... News) -- Prostaglandin analogue eye drops -- a common ... of vision loss in patients with the eye disease, ... David Garway-Heath, of the Moorfields Eye Hospital and UCL ... than 500 people newly diagnosed with open-angle glaucoma -- ... of the leading causes of blindness. About 45 ...
(Date:12/17/2014)... RI (PRWEB) December 17, 2014 ... recognize private practices that have made outstanding and ... in support and progression of private practice physical ... American Physical Therapy Association. , On behalf of ... OCS, owner and CEO of Performance accepted the ...
Breaking Medicine News(10 mins):Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 2Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 3Health News:Garth Brooks Tickets for Joe Louis Arena: Ticketability.com Becomes a Popular Destination for Discount Tickets for Garth Brooks’ Detroit Concerts Set for February 27-28 2Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2
... minister Andy Kerr has ordered the closure of two hospitals ... close the hospitals in the border as part of a ... the 80-year-old nine-bed Queen Margaret Hospital in Jedburgh and the ... worked hard to save the community hospitals. The Jedburgh Provost ...
... of laws was initiated by Quebec Health Minister Philippe Couillard ... health-care insurance //. ,The Supreme Court of Canada ... on June 9, 2005,ruling that Quebec had failed to prove ... medicare, was justified. However with the development of Bill ...
... fast-growing medical tourism industry is set to get a ... the entire range of medicare facilities overseas//. ,Global ... a leading travel firm, have signed an agreement to ... Africa, Canada and the Middle East. ...
... study has shed light on a different dimension to ... during childhood. // Insecure feelings experienced during childhood and ... of one’s body that can translate into an eating ... very early due to insecure attachment and separation anxiety. ...
... women, women overweight in their teens or later are at ... was conducted by scientists at the University of Pittsburgh Medical ... 2,110 women with and without ovarian cancer. The study of ... in recent years or at the age of 18, were ...
... boy’s divorced parents, whether to circumcise their son or not. ... inflammation in last year, his mother needs her son to be ... is fine and if circumcision was done it will result in ... 2003 divorce decree has given the rights to decide on the ...
Cached Medicine News:Health News:Quebecers To Choose Private Health-Care Insurance 2Health News:Plan to Promote the Medicare Facilities of India to Abroad 2
(Date:12/17/2014)... 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... of enrollment in its first Phase 2a study, ... confirmed the 1-month findings that were reported in ... - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/bf3b6l/electrocardiogram ) has ... - Global Trends, Estimates and Forecasts, 2012-2018" report ... Global Electrocardiogram Devices (ECG) sector is ... North America accounts for nearly 36% ... Europe claims approximately 27% (2018). ...
(Date:12/15/2014)... , Dec. 15, 2014  Inovio Pharmaceuticals, Inc. ... has been added to the NASDAQ Biotechnology Index ... will become effective upon market open on December ... is designed to track the performance of a ... either biotechnology or pharmaceutical according to the Industry ...
Breaking Medicine Technology:RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4
... 18, 2011 What:   ... analysis of FDA,s 510(k) regulatory pathway—through which more than ... within it. The study is the most comprehensive survey ... FDA,s Center for Devices and Radiological Health (CDRH) is ...
... DIEGO, May 18, 2011 aTyr Pharma ... that Melissa Ashlock, M.D., has joined as vice ... Ashlock,s experience in translating novel biology into drug ... team in the development of innovative therapeutic approaches ...
Cached Medicine Technology:Findings From Largest Industry Assessment of 510(k) Process to be Released on May 24, 2011 2Translational Science Expert, Dr. Melissa Ashlock, Joins aTyr Pharma to Advance Physiocrine-based Therapeutics 2Translational Science Expert, Dr. Melissa Ashlock, Joins aTyr Pharma to Advance Physiocrine-based Therapeutics 3
Used for introducing a Foley catheter (up to 18.0 French in size) suprapubically into the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
Used to establish and temporarily maintain suprapubic access during endoscopic procedures. Supplied sterile in peel-open packages. Intended for one-time use....
Used for pulling sutures from a vaginal incision into the suprapubic area during bladder suspension surgery. Supplied sterile in peel-open packages....
Stratasis Urethral Sling is intended for implantation to reinforce soft tissues where weakness exists. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: